Mpox (monkeypox) pathfinder

CDNA's (Communicable Diseases Network) interim guidelines describe recommended public health responses to cases and contacts of monkeypox virus infection. CDNA will continue to review these guidelines as more information becomes available.

This paper outlines AFAO and ASHM’s policy position on the collection and dissemination of mpox surveillance data. This paper notes that states and territories should issue mpox surveillance data relating to locally acquired cases as soon as possible as well as data relating to cases among returned travellers. | | AFAO (Australian Federation of AIDS Organisations) [AFAO has rebranded as Health Equity Matters] + ASHM (Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine).

This interim guidance applies to all countries and covers surveillance, case investigation and contact-tracing for mpox.

The aim of this document is to provide advice and considerations, based on currently available evidence, to EU/EEA public health authorities at national, regional or local levels, conducting contact tracing in the context of the ongoing monkeypox outbreak. This advice and considerations encompass the prioritisation of efforts to identify and manage close contacts, as well as provide indicators that can be used for monitoring the efficacy of contact tracing activities. | ECDC's (European Centre for Disease Prevention and Control) for the EU/EEA (European Economic Area).

Covers: Public health management of cases; and Public health management of contacts. PHAC (Public Health Agency Canada).

Classification of contacts and follow-up advice for non-high consequence infectious disease (HCID) mpox. This guidance provides principles for risk assessment and follow-up of contacts of confirmed mpox cases. It is intended to support risk assessment and categorisation of contacts to ensure they are offered appropriate public health and isolation advice.

Information sheets for category 2 and category 3 contacts.

CDNA's (Communicable Diseases Network) surveillance case definition for monkeypox virus infection, which is nationally notifiable within Australia.

Public Health Laboratory Network's (PHLN) standard laboratory case definition for the diagnosis of monkeypox in Australia.

The Toolbox includes the WHO mpox case definitions; data collection tools and laboratory confirmation guidance. | WHO (World Health Organization).

This summary covers the epidemiology, diagnosis, management and follow up treatment for mpox. Includes coverage of vaccines and therapeutics.

This topic reviews the virology, epidemiology, clinical manifestations, and diagnosis of mpox.

This is the WA DoH's weekly report on all notifiable diseases in the State, including: *regional and metropolitan breakdowns; *comparison to the same number of weeks in previous years, and the *breakdown over the previous 8 weeks for short term comparison. | WA Department of Health.

This situation report provides an overview of the mpox epidemiological situation in the WHO African Region, on a weekly basis (as of August 2024), as well as the global epidemiological situation on a monthly basis (as of July 2024).

An essential instrument for the rapid and accurate dissemination of epidemiological information on cases and outbreaks of diseases under the International Health Regulations and on other communicable diseases of public health importance, including emerging or re-emerging infections. An electronic bilingual English/French version of the WER is accessible every Friday and can be downloaded free of charge.

ECDC epidemiological update on the current mpox virus clade 1 outbreak, 26 Aug 2024. | EU ECDC (European Centre for Disease Prevention and Control).

ECDC's risk assessment for the European Economic Area (EU/EEA). | EU ECDC (European Centre for Disease Prevention and Control).

Weekly summary of all information gathered through epidemic intelligence activities regarding communicable diseases of concern to the EU. It also provides updates on the global situation and changes in the epidemiology of communicable diseases with potential to affect Europe. | EU ECDC (European Centre for Disease Prevention and Control).

This quarterly report provides an overview of the total number of cases of mpox (monkeypox) reported to the ECDC (European Centre for Disease Prevention and Control) and the WHO Regional Office for Europe through IHR/EWRS mechanisms.

Coverage includes: progression of the outbreak over time and place; populations impacted by the outbreak; symptoms; vaccinations; and technical notes. | PHAC (Public Health Agency Canada).

A monthly overview of the current mpox (monkeypox) outbreak in the UK.

Technical briefing documents on the investigation into cases of monkeypox in England.

Weekly data from UK laboratories on the number of cases of notifiable bacteria and viruses.

Covers: Risk of mpox (monkeypox) spreading between people and animals; Animals susceptible to mpox (monkeypox); Pets and mpox (monkeypox); Signs of mpox (monkeypox) in animals; and Testing for mpox (monkeypox) in animals. | PHAC (Public Health Agency Canada).

Live information on the case numbers for mpox in Australia. | AU Department of Health and Aging.

WANIDD is maintained by the WA DoH's Communicable Disease Control Directorate, Public and Aboriginal Health Division.

The data summarised in the graphs and tables on the dashboard that are sourced from WANIDD.

The platform collects patient-level anonymized clinical data to understand of clinical features and outcomes of mpox.

This compilation of images of mpox lesions shows examples of the effects of monkeypox virus infection on the skin and mucosa. The Atlas will support those collecting data to harmonise their assessments of lesions,and improve the quality of the collected data. It has been developed in parallel with the emergency use protocol for tecovirimat for mpox under the MEURI framework.

An initiative of the AAD (American Academy of Dermatology Association) and the ILDS (International League of Dermatologic Societies). Physicians and health care professionals from all countries who are treating patients with mpox are invited to submit case reports. The hope is that the information provided will help to understand dermatologic manifestations of the mpox (monkeypox) virus, as well as skin reactions to the mpox vaccine. Information and updates will be shared via the mpox American Academy of Dermatology website.